PLUS THERAPEUTICS, INC.

Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.

PSTV | US

Overview

Corporate Details

ISIN(s):: US23283K2042 (+1 more)
LEI:
Country:: United States of America
Address:: 4200 MARATHON BLVD., 78756 AUSTIN
Website:: http://www.plustherapeutics.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers in adults and children. The company's proprietary platform is designed to deliver a single, high-dose of radiation directly to tumors while minimizing damage to healthy tissue. This is achieved by encapsulating Rhenium radioisotopes within novel delivery systems like nanoliposomes and biodegradable microspheres. Its lead drug candidate, REYOBIQ™ (rhenium Re186 obisbemeda), targets central nervous system (CNS) cancers, including glioblastoma and leptomeningeal metastases. The company's pipeline also includes a next-generation therapy for solid organ cancers, such as liver cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PLUS THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PLUS THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for PLUS THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Immuron Ltd Develops oral antibodies from bovine colostrum for digestive and immune health.	United States of America	IMRN
IMPACT BIOMEDICAL INC. Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.	United States of America	IBO
Imunon, Inc. Developing DNA-based immunotherapies for oncology and infectious diseases.	United States of America	IMNN
IN8BIO, INC. Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.	United States of America	INAB
Incanthera plc Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.	United Kingdom	INC
INCYTE CORP Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.	United States of America	INCY
Indaptus Therapeutics, Inc. Develops immunotherapies using engineered bacteria to treat cancer and viral infections.	United States of America	INDP
Indivior PLC Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.	United Kingdom	INDV
Infant Bacterial Therapeutics Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.	Sweden	IBT
InflaRx N.V. Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.	United States of America	IFRX